Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | AR | P10275 | 2/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 3/20 | 0.33 |
| ▸ | BRD2 | P25440 | 2/20 | 0.33 |
| ▸ | BRD3 | Q15059 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | TAS2R8 | Q9NYW2 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13879570 | 0.96 | KMT2A (0.41) | KMT2AARCHRM4POLBALDH1A1 | |
| SCHEMBL13879493 | 0.73 | ALDH1A1 (0.60) | ALDH1A1GAATAS2R8 | |
| SCHEMBL13879401 | 0.67 | AR (0.46) | KMT2AARPOLBALDH1A1 | |
| SCHEMBL13693056 | 0.67 | SMN1; SMN2 (0.44) | KMT2APOLBALDH1A1SMN1; SMN2 | |
| SCHEMBL13879562 | 0.66 | TAS2R8 (0.60) | BRD4TAS2R8 | |
| SCHEMBL5740800 | 0.66 | KMT2A (0.66) | KMT2AARALDH1A1GAA | |
| SCHEMBL13879492 | 0.65 | AR (0.53) | KMT2AARPOLBALDH1A1SMN1; SMN2 | |
| SCHEMBL27542205 | 0.65 | ALDH1A1 (0.45) | CHRM4BRD4BRD2BRD3ALDH1A1 | |
| SCHEMBL9781204 | 0.65 | AR (0.40) | KMT2AARPOLBALDH1A1 | |
| SCHEMBL13879514 | 0.64 | ALDH1A1 (0.60) | KMT2AARPOLBALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099186-A1 | INHIBITORS OF VIRAL REPLICATION | INTERMUNE, INC. | 2009-04-16 | — | — | US | disclosed |
| US-20090099186-A1 | INHIBITORS OF VIRAL REPLICATION | INTERMUNE, INC. | 2009-04-16 | — | — | US | disclosed |
| WO-2007047146-A2 | INHIBITORS OF VIRAL REPLICATION | INTERMUNE, INC. (US) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099186-A1 | INHIBITORS OF VIRAL REPLICATION | EIF2AK2, HAVCR2, RTF2 | KMT2A 2463/4885AR 4274/4885CHRM4 4642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.